Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jul 26, 2021; 13(7): 825-840
Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.825
Bone marrow mononuclear cells for joint therapy: The role of macrophages in inflammation resolution and tissue repair
Bruno C Menarim, James N MacLeod, Linda A Dahlgren
Bruno C Menarim, James N MacLeod, Gluck Equine Research Center, Department of Veterinary Science, College of Agriculture, Food and Environment, University of Kentucky, Lexington, KY 40546, United States
Linda A Dahlgren, Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, United States
Author contributions: Menarim BC collected the data and developed the main conceptual ideas; MacLeod JN and Dahlgren LA contributed with additional conceptual ideas; all authors contributed to the writing, edition and revision of the manuscript, and approved the final version.
Conflict-of-interest statement: We have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bruno C Menarim, DVM, MSc, PhD, Senior Postdoctoral Fellow, Gluck Equine Research Center, Department of Veterinary Science, College of Agriculture, Food and Environment, University of Kentucky, 1400 Nicholasville, Lexington, KY 40546, United States. bruno.menarim@uky.edu
Received: February 21, 2021
Peer-review started: February 21, 2021
First decision: April 20, 2021
Revised: May 3, 2021
Accepted: June 22, 2021
Article in press: June 22, 2021
Published online: July 26, 2021
Processing time: 151 Days and 15.4 Hours
Abstract

Osteoarthritis (OA) is the most prevalent joint disease causing major disability and medical expenditures. Synovitis is a central feature of OA and is primarily driven by macrophages. Synovial macrophages not only drive inflammation but also its resolution, through a coordinated, simultaneous expression of pro- and anti-inflammatory mechanisms that are essential to counteract damage and recover homeostasis. Current OA therapies are largely based on anti-inflammatory principles and therefore block pro-inflammatory mechanisms such as prostaglandin E2 and Nuclear factor-kappa B signaling pathways. However, such mechanisms are also innately required for mounting a pro-resolving response, and their blockage often results in chronic low-grade inflammation. Following minor injury, macrophages shield the damaged area and drive tissue repair. If the damage is more extensive, macrophages incite inflammation recruiting more macrophages from the bone marrow to maximize tissue repair and ultimately resolve inflammation. However, sustained damage and inflammation often overwhelms pro-resolving mechanisms of synovial macrophages leading to the chronic inflammation and related tissue degeneration observed in OA. Recently, experimental and clinical studies have shown that joint injection with autologous bone marrow mononuclear cells replenishes inflamed joints with macrophage and hematopoietic progenitors, enhancing mechanisms of inflammation resolution, providing remarkable and long-lasting effects. Besides creating an ideal environment for resolution with high concentrations of interleukin-10 and anabolic growth factors, macrophage progenitors also have a direct role in tissue repair. Macrophages constitute a large part of the early granulation tissue, and further transdifferentiate from myeloid into a mesenchymal phenotype. These cells, characterized as fibrocytes, are essential for repairing osteochondral defects. Ongoing “omics” studies focused on identifying key drivers of macrophage-mediated resolution of joint inflammation and those required for efficient osteochondral repair, have the potential to uncover ways for developing engineered macrophages or off-the-shelf pro-resolving therapies that can benefit patients suffering from many types of arthropaties, not only OA.

Keywords: Osteoarthritis; Arthropathy; Synovitis; Hematopoietic progenitor; Homeostasis; Cell therapy

Core Tip: Synovial macrophages are essential for joint integrity. Following injury, macrophages incite inflammation recruiting more macrophages from the bone marrow to counteract damage and promote tissue repair. Synovial macrophages are further essential to resolve inflammation recovering joint homeostasis. However, sustained damage frequently overwhelms pro-resolving functions of synovial macrophages, leading to chronic inflammation and degeneration. This review summarizes the dual role of macrophages in the maintenance of joint homeostasis and the emergent therapeutic use of macrophage progenitors isolated from the bone marrow to promote endogenous resolution of joint inflammation and recovery of homeostasis, while preserving physiological mechanisms negatively affected by anti-inflammatories.